Auryan Szalat1, Shoshana Shpitzen2, Anat Tsur3, Ilana Zalmon Koren4, Shmuel Shilo3, Liana Tripto-Shkolnik5, Ronen Durst2, Eran Leitersdorf2, Vardiella Meiner6. 1. Endocrinology and Metabolism Service, Department of Internal Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. auryans@hadassah.org.il. 2. Center for Research, Prevention and Treatment of Atherosclerosis, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 3. Endocrinology and Metabolism Service, Department of Internal Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 4. Pediatric Endocrinology, Armon Child Center, Carmel Hospital, Clalit Health Service, Haifa, Israel. 5. Endocrinology Department, Chaim Sheba Medical Center, Tel Ha Shomer, Ramat Gan, Israel. 6. Department of Genetics and Metabolic diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Abstract
PURPOSE: Patients with familial hyperparathyroidism and low urinary calcium excretion may have familial hypocalciuric hypercalcemia (FHH) with mutations in one of three genes: the calcium-sensing receptor (CaSR) defining FHH-type 1, the adaptor-related protein complex 2 (AP2S1) related to FHH-type 3 or the G-protein subunit alpha11 (GNA11) associated with FHH-type 2. We aimed to evaluate the presence of mutations in these genes and to identify phenotypic specificities and differences in these patients. SUBJECTS AND METHODS: Selected patients were recruited for genetic evaluation. After informed consent was signed, blood for DNA extraction was obtained and genetic sequencing of CaSR was done. In negative cases, we further performed sequencing of AP2S1 and GNA11. RESULTS: A total of 10 index cases were recruited. CaSR sequencing yielded three missense heterozygous mutations (30%): c.554G > A (p.I32V) previously characterized by our team, c.1394 G > A (p.R465Q) and a novel expected disease-causing mutation c.2479 A > C (p.S827R). We identified 2 additional patients (20%) carrying the deleterious recurrent mutation c.44G > T (p.R15L) in the AP2S1 gene. No GNA11 mutation was found. Clinically, patients with AP2S1 mutations had significant cognitive and behavioral disorders, and higher blood calcium and magnesium levels than patients with FHH1. CONCLUSION: CaSR and AP2S1 sequencing is worthwhile in patients with familial hyperparathyroidism and phenotype suggesting FHH as it can diagnose up to 50% of cases. GNA11 mutations seem much rarer. Learning disabilities in these patients, associated with higher serum calcium and magnesium levels may suggest the presence of AP2S1 rather than CaSR mutation and may guide the first step in the genetic evaluation.
PURPOSE:Patients with familial hyperparathyroidism and low urinary calcium excretion may have familial hypocalciuric hypercalcemia (FHH) with mutations in one of three genes: the calcium-sensing receptor (CaSR) defining FHH-type 1, the adaptor-related protein complex 2 (AP2S1) related to FHH-type 3 or the G-protein subunit alpha11 (GNA11) associated with FHH-type 2. We aimed to evaluate the presence of mutations in these genes and to identify phenotypic specificities and differences in these patients. SUBJECTS AND METHODS: Selected patients were recruited for genetic evaluation. After informed consent was signed, blood for DNA extraction was obtained and genetic sequencing of CaSR was done. In negative cases, we further performed sequencing of AP2S1 and GNA11. RESULTS: A total of 10 index cases were recruited. CaSR sequencing yielded three missense heterozygous mutations (30%): c.554G > A (p.I32V) previously characterized by our team, c.1394 G > A (p.R465Q) and a novel expected disease-causing mutation c.2479 A > C (p.S827R). We identified 2 additional patients (20%) carrying the deleterious recurrent mutation c.44G > T (p.R15L) in the AP2S1 gene. No GNA11 mutation was found. Clinically, patients with AP2S1 mutations had significant cognitive and behavioral disorders, and higher blood calcium and magnesium levels than patients with FHH1. CONCLUSION:CaSR and AP2S1 sequencing is worthwhile in patients with familial hyperparathyroidism and phenotype suggesting FHH as it can diagnose up to 50% of cases. GNA11 mutations seem much rarer. Learning disabilities in these patients, associated with higher serum calcium and magnesium levels may suggest the presence of AP2S1 rather than CaSR mutation and may guide the first step in the genetic evaluation.
Authors: Dominika Babińska; Marcin Barczyński; Tomasz Stefaniak; Tomasz Osęka; Anna Babińska; Dariusz Babiński; Krzysztof Sworczak; Andrzej J Lachiński; Wojciech Nowak; Zbigniew Sledziński Journal: Langenbecks Arch Surg Date: 2011-12-08 Impact factor: 3.445
Authors: Fadil M Hannan; M Andrew Nesbit; Chen Zhang; Treena Cranston; Alan J Curley; Brian Harding; Carl Fratter; Nigel Rust; Paul T Christie; Jeremy J O Turner; Manuel C Lemos; Michael R Bowl; Roger Bouillon; Caroline Brain; Nicola Bridges; Christine Burren; John M Connell; Heike Jung; Eileen Marks; David McCredie; Zulf Mughal; Christine Rodda; Sherida Tollefsen; Edward M Brown; Jenny J Yang; Rajesh V Thakker Journal: Hum Mol Genet Date: 2012-03-14 Impact factor: 6.150
Authors: Geoffrey N Hendy; Lucie Canaff; Ron S Newfield; Liana Tripto-Shkolnik; Betty Y L Wong; Bonnie S P Lee; David E C Cole Journal: J Clin Endocrinol Metab Date: 2014-04-14 Impact factor: 5.958
Authors: Sarah A Howles; Fadil M Hannan; Valerie N Babinsky; Angela Rogers; Caroline M Gorvin; Nigel Rust; Tristan Richardson; Malachi J McKenna; M Andrew Nesbit; Rajesh V Thakker Journal: N Engl J Med Date: 2016-04-07 Impact factor: 91.245
Authors: M Andrew Nesbit; Fadil M Hannan; Sarah A Howles; Valerie N Babinsky; Rosie A Head; Treena Cranston; Nigel Rust; Maurine R Hobbs; Hunter Heath; Rajesh V Thakker Journal: N Engl J Med Date: 2013-06-27 Impact factor: 91.245
Authors: Fadil M Hannan; Sarah A Howles; Angela Rogers; Treena Cranston; Caroline M Gorvin; Valerie N Babinsky; Anita A Reed; Clare E Thakker; Detlef Bockenhauer; Rosalind S Brown; John M Connell; Jacqueline Cook; Ken Darzy; Sarah Ehtisham; Una Graham; Tony Hulse; Steven J Hunter; Louise Izatt; Dhavendra Kumar; Malachi J McKenna; John A McKnight; Patrick J Morrison; M Zulf Mughal; Domhnall O'Halloran; Simon H Pearce; Mary E Porteous; Mushtaqur Rahman; Tristan Richardson; Robert Robinson; Isabelle Scheers; Haroon Siddique; William G Van't Hoff; Timothy Wang; Michael P Whyte; M Andrew Nesbit; Rajesh V Thakker Journal: Hum Mol Genet Date: 2015-06-16 Impact factor: 6.150
Authors: Sunita M C De Sousa; Richard W Carroll; Alex Henderson; John Burgess; Roderick J Clifton-Bligh Journal: Endocrine Date: 2021-11-13 Impact factor: 3.633
Authors: Caroline M Gorvin; Raghu Metpally; Victoria J Stokes; Fadil M Hannan; Sarath B Krishnamurthy; John D Overton; Jeffrey G Reid; Gerda E Breitwieser; Rajesh V Thakker Journal: Hum Mol Genet Date: 2018-03-01 Impact factor: 6.150
Authors: Felix Chi Kin Wong; Wai Sheung Wong; Jeffrey Sung Shing Kwok; Teresa Kam Chi Tsui; Kam Piu Lau; Michael Ho Ming Chan; Yuet Ping Yuen Journal: F1000Res Date: 2019-09-09
Authors: Ridge Dershem; Caroline M Gorvin; Raghu P R Metpally; Sarathbabu Krishnamurthy; Diane T Smelser; Fadil M Hannan; David J Carey; Rajesh V Thakker; Gerda E Breitwieser Journal: Am J Hum Genet Date: 2020-05-07 Impact factor: 11.025
Authors: Noha N Mukhtar; Mohei El-Din M Abouzied; Mohammed H Alqahtani; Muhammad M Hammami Journal: BMC Endocr Disord Date: 2021-01-26 Impact factor: 2.763
Authors: Fadil M Hannan; Mark Stevenson; Asha L Bayliss; Victoria J Stokes; Michelle Stewart; Kreepa G Kooblall; Caroline M Gorvin; Gemma Codner; Lydia Teboul; Sara Wells; Rajesh V Thakker Journal: Hum Mol Genet Date: 2021-05-29 Impact factor: 6.150
Authors: Marta Onopiuk; Bonnie Eby; Vasyl Nesin; Peter Ngo; Megan Lerner; Caroline M Gorvin; Victoria J Stokes; Rajesh V Thakker; Maria Luisa Brandi; Wenhan Chang; Mary Beth Humphrey; Leonidas Tsiokas; Kai Lau Journal: JCI Insight Date: 2020-04-23